当前位置：首页 > 文献互助 > 互助详情

Benzgalantamine (Zunveyl) for the Treatment of Mild to Moderate Alzheimer Disease复制

用户bEcv-rzIERoU 3小时前 26 10 求助中 帖子自动结束时间: 2025-10-14 14:44:56

1. 文件大小不能超过300M, 允许上传文档或压缩包等

2. 请确保上传文献的真实性、完整性，不得对原文做任何修改

注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规

DOI:复制

文献链接:复制

其他信息:

EM Johnston, JL Lounsbery
American family physician, 2025
aafp.org
Benzgalantamine should improve cognitive and behavioral symptoms in patients with mild to moderate Alzheimer disease over the short-term, similarly to galantamine. Given the frequent intolerance of galantamine, benzgalantamine can be considered if intolerance occurs.

上一篇：Efficacy and safety of novel fixed dose combination of vilanterol, glycopyrronium, and fluticasone furoate dry powder inhaler: A phase 3, randomized, non-inferiority trial compared with fixed dose combination of indacaterol,

下一篇：GPR37L1 identifies spinal cord astrocytes and protects neuropathic pain after nerve injury

互助时间线

2025-10-09 14:44:56 [发起求助]

最新发布的求助

Expanded Combined Loading Injury Criterion for the Human Lumbar Spine Under Dynamic Compression 1小时前
Nephrotoxicity related to new therapeutic compounds 1小时前
Study in Nature Electronics: An electrically conductive silver–polyacrylamide–alginate hydrogel composite for soft electronics 1小时前
The Effect of Surgical Approach and Hip Offset Reconstruction on Gait Biomechanics Following Total Hip Arthroplasty 2小时前
Benzgalantamine (Zunveyl) for Alzheimer's Disease 2小时前
The Radiopharmaceutical Chemistry of the Halogen Radionuclides 2小时前
RSV prophylaxis in premature infants 3小时前
GPR37L1 identifies spinal cord astrocytes and protects neuropathic pain after nerve injury 3小时前
Benzgalantamine (Zunveyl) for the Treatment of Mild to Moderate Alzheimer Disease 3小时前
Efficacy and safety of novel fixed dose combination of vilanterol, glycopyrronium, and fluticasone furoate dry powder inhaler: A phase 3, randomized, non-inferiority trial compared with fixed dose combination of indacaterol, 3小时前
Recaticimab in adult heterozygous familial hypercholesterolemia (REMAIN-3): A multicentre, randomised, double-blind, placebo-controlled phase 3 study 3小时前
Product Class 10: Amido Derivatives of Sulfanediol 4小时前

wispass工作室 Copyright © 蜀ICP备2024051606号-2 www.wispass.com